Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Stevens Capital Management LP

Stevens Capital Management LP increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 18.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,090 shares of the medical research company’s stock after acquiring an additional 2,311 shares during the period. Stevens Capital Management LP’s holdings in Edwards Lifesciences were worth $1,151,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $34,000. Operose Advisors LLC increased its position in shares of Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares in the last quarter. SRS Capital Advisors Inc. boosted its position in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after buying an additional 474 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $52,000. Finally, ORG Partners LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $66,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent research reports. Mizuho raised their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Royal Bank of Canada raised their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. Oppenheimer boosted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Piper Sandler increased their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Stifel Nicolaus upped their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Edwards Lifesciences Trading Down 1.8 %

Shares of Edwards Lifesciences stock traded down $1.58 during trading hours on Friday, reaching $86.43. The stock had a trading volume of 4,979,943 shares, compared to its average volume of 3,844,076. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.61, a P/E/G ratio of 4.39 and a beta of 1.05. The firm has a 50 day simple moving average of $90.27 and a two-hundred day simple moving average of $78.76.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares in the company, valued at $2,980,774.68. The disclosure for this sale can be found here. In the last three months, insiders sold 194,004 shares of company stock worth $17,166,254. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.